Related Experiment Video
Updated: Feb 15, 2026

A Modified Method for Heterotopic Mouse Heart Transplantion
Published on: June 23, 2014
Profound Vasoplegia During Sacubitril/Valsartan Treatment After Heart Transplantation
Aws Almufleh1, Lisa M Mielniczuk2, Radoslav Zinoviev3
1Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Cardiac Sciences Department, King Saud University, Riyadh, Saudi Arabia.
Insights
Sacubitril/valsartan may cause severe hypotension after heart transplantation (HT), leading to complications like acute kidney injury. Consider withholding this medication before HT in at-risk patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Vasoplegia is a serious complication after heart transplantation (HT), affecting up to 16% of patients.
- It is linked to increased morbidity and mortality, posing a significant clinical challenge.
Observation:
- A 61-year-old man with ischemic cardiomyopathy developed profound hypotension post-HT while on sacubitril/valsartan.
- Despite treatment with methylene blue and vasopressors, he experienced acute kidney injury requiring dialysis and prolonged ICU stay.
Findings:
- This case highlights a potential potent vasodilatory effect of sacubitril/valsartan.
- The drug may exacerbate or contribute to vasoplegia in the post-HT setting.
Implications:
- Clinicians should consider the potential for severe hypotension when patients on sacubitril/valsartan undergo HT.
- Withholding sacubitril/valsartan before HT, especially in patients with vasoplegia risk factors, may be warranted.
- Further studies are needed to confirm these findings and guide clinical practice.
Abstract:
Vasoplegia occurs in up to 16% of patients who undergo heart transplantation (HT) and is associated with significant morbidity and mortality. We present a case of a 61-year-old man with ischemic cardiomyopathy receiving sacubitril/valsartan (Entresto; Novartis, Cambridge, MA) who developed profound hypotension after HT. He was treated with intravenous methylene blue and high-dose vasopressors, but developed acute kidney injury requiring dialysis and a prolonged stay in the intensive care unit. This case supports a potent vasodilatory effect of sacubitril/valsartan, and if confirmed by other studies, might warrant consideration for withholding treatment while awaiting HT, particularly in patients with risk factors for vasoplegia.
Related Concept Videos
Anatomy of the Heart
Anatomy of the Heart
The heart has three layers: the innermost endocardium, the muscular myocardium, and the outer epicardium, all working together for optimal cardiac function.
Chambers of the Heart
The heart is made up of four...
Overview of the Heart
The heart's structure...
Conduction System of the Heart
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
Conduction System of the Heart
This system relies on the unique properties of nodal and Purkinje cells:...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

